SOURCE: Medpace


February 10, 2010 10:00 ET

Medpace Announces the Addition of Samer E. Kaba, MD, Medical Director, Strengthening Therapeutic Expertise in Neuroscience Drug Development Services

CINCINNATI, OH--(Marketwire - February 10, 2010) - Medpace, Inc. today announced the addition of Samer E. Kaba, MD, as a Medical Director with therapeutic expertise in guiding global clinical trials in the area of Neuroscience. Dr. Kaba brings a wealth of clinical development expertise in the areas of neurology, psychiatry, and analgesia. As a Medpace Medical Director, Dr. Kaba will be engaged with Medpace clients in formulating clinical development plans and strategy, designing clinical trials, and providing medical oversight for clinical trials in his areas of expertise. Dr. Kaba joins an experienced neurology operations team specifically in Parkinson's, Alzheimer's, multiple sclerosis, and pain.

"The addition of Dr. Samer Kaba strengthens the Medpace position supporting our sponsors who are advancing new drugs for central nervous system diseases, one of the largest groups of drugs currently in development by biopharmaceutical sponsors," said Jonathan Isaacsohn, MD, FACC, Executive Vice President, Medpace. "Dr. Kaba's experience and industry knowledge will allow us to provide strategic consultation to our sponsors in designing innovative clinical trial methods for many of our customers engaged in bringing new drugs to market in this therapeutic area."

Prior to joining Medpace, Dr. Kaba served as the VP of Clinical Development and Chief Medical Officer at Camargo Pharmaceutical Services, VP & Global Head of Medical Affairs and Strategic Product Development at Premier Research, and Sr. Director of Global Product Development at PRA International. In addition to his large expertise in drug development, Dr. Kaba has over 20 years experience in managing patients with neurological conditions.

Prior to joining the pharmaceutical industry, Dr. Kaba held multiple academic positions at the University of Texas, University of Arkansas, and maintained a neurology private practice. He continues to hold the position of Clinical Assistant Professor of Neurology at Emory University. Dr. Kaba completed his medical degree at the Damascus University School of Medicine in Syria, and his post-graduate work at the State University of New York at Buffalo. He also completed fellowship training in Neuro-immunology (Multiple Sclerosis) at the State University of New York at Buffalo, and in Neuro-oncology at the University of Texas M.D. Anderson Cancer Center, in Houston, TX. Dr. Kaba is board-certified by the American Board of Psychiatry and Neurology. He is an active member of the American Academy of Neurology, Society for Neuro-Oncology, American Society of Clinical Oncology, and American Academy of Pharmaceutical Physicians. He has many scientific publications and book chapters to his credit, and has been an invited speaker at several scientific conferences.


Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009 CenterWatch Site Survey.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and centralized imaging core laboratory management and reading from Imagepace.

Visit the Medpace website at

Contact Information